RxDoctor Payments Data

Kiley Toder, MD

Internal Medicine · Johnston, RINPI 1063640225

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (49.7%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Pfizer accounts for 74.1% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $5,303 and has fallen 97.6% since, to $125 in 2023. Among internal medicine clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,646in general payments, 2019–2025

Across 30 payments — averaging $221.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$5K
  • Amgen$1K
  • Hikma Pharmaceuticals USA$186
  • AstraZeneca$138
  • AbbVie$123

What the payments were for

  • Consulting fees$3,30050%
  • Speaking & faculty fees$1,00015%
  • Travel & lodging$1,36621%
  • Food & beverage$98015%

General payments by program year

19
20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer6$4,928
Amgen(2 entities)5$1,272
Hikma Pharmaceuticals USA10$186
AstraZeneca2$138
AbbVie7$123

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,646 in reported general payments places this provider in the 95th percentile of 808 internal medicine providers in Rhode Island.

See all internal medicine providers in Rhode Island

Medicare billing

Part B allowed, 2024
$1,925,380
Medicare patients
365
Services billed
154,655

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept92$700,266
XeljanzTofacitinib Citrate79$457,929
Humira(Cf) PenAdalimumab59$433,065
Enbrel MiniEtanercept23$189,264
ActemraTocilizumab29$158,232
EnbrelEtanercept20$142,760
TymlosAbaloparatide20$60,043
MethotrexateMethotrexate Sodium373$10,660
Allopurinol474$7,312
Hydroxychloroquine Sulfate159$6,853
Colchicine83$5,828
Cevimeline Hcl20$5,166
Celecoxib114$3,421
Leflunomide32$3,234
Febuxostat21$3,072

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerXeljanz$4,928$457,92979 claims
AmgenEnbrel$1,272$142,76020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 808 internal medicine providers in Rhode Island.

Other internal medicine in Johnston

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →